Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behçet's disease on infliximab therapy

British Journal of Ophthalmology

Volumn 95, Issue 9, 2011, Pages 1245-1250

  Keino, Hiroshi ^a   Okada, Annabelle A ^a   Watanabe, Takayo ^a   Taki, Wakako ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; CYCLOSPORIN; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISONIAZID; METHOTREXATE; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ANTERIOR EYE CHAMBER; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL PHARYNGITIS; BEHCET DISEASE; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL OBSERVATION; COMMON COLD; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; EYE INFLAMMATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; OPTIC DISK; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; RESPIRATORY DISTRESS; RETINA; RETINA MACULA LUTEA; RETINAL VASCULAR LEAKAGE; RETROSPECTIVE STUDY; SEVERE INFUSION REACTION; SIDE EFFECT; TREATMENT DURATION; TUBERCULOSIS; UVEORETINITIS; VISUAL ACUITY;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OPTIC DISK; RETINA; RETINITIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY; YOUNG ADULT;

EID: 80052132365     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.194464     Document Type: Article

References (23)

1. Mochizuki M, Akduman L, Nussenblatt RB. Behçet's disease. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular Infection and Immunity. St Louis, MO: Mosby, 1996:663-75.
2. Nussenblatt RB. Uveitis in Behçet's disease. Int Rev Immunol 1997;14:67-79.
3. Yates PA, Michelson JB. Behçet's disease. Int Ophthalmol Clin 2006;46:209-33.
4. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behçet's disease: an analysis of 880 patients. Am J Ophthalmol 2004;138:373-80. (Pubitemid 39208563)
5. Takeuchi M, Hokama H, Tsukahara R, et al. Risk and prognostic factors of poor visual outcome in Behçet's disease with ocular involvement. Graefe's Arch Clin Exp Ophthalmol 2005;243:1147-52. (Pubitemid 43124166)
6. Kaburaki T, Araki F, Takamoto M, et al. Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet's disease. Graefe's Arch Clin Exp Ophthalmol. Published online first: 08 Dec 2009. doi:10.1007/s00417-009-1234-z.
7. George RK, Chan C, Whitcup SM, et al. Ocular immunopathology of Behçet's disease. Surv Ophthalmol 1997;42:157-162.
8. Okada AA. Behçet's disease: general concepts and recent advances. Curr Opin Ophthalmol 2006;17:551-6. (Pubitemid 44655589)
9. Nahar IK, Shojania K, Marra CA, et al. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann Pharmacother 2003;37:1256-65. (Pubitemid 37040219)
10. Ohno S, Nakamura S, Hori S, et al. Efficacy, Safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rhematol 2004;31:1362-8. (Pubitemid 38879203)
11. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease. Arthritis Rheum 2005;52:2478-84. (Pubitemid 41117435)
12. International study group for Behçet's disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-80.
13. Behçet's disease research committee of Japan. Behçet's disease: guide to diagnosis of Behçet's disease. Jpn J Ophthalmol 1974;18:291-4.
14. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63. (Pubitemid 28459913)
15. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Eng J Med 2003;348:601-8. (Pubitemid 36204954)
16. The Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-16.
17. Niccoli L, Nannini C, Benucci M, et al. Long term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology 2007;46:1161-4. (Pubitemid 47050622)
18. Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus siclosporine during the initial 6-month treatment period in Behçet's disease. Br J Ophthalmol 2010;94:284-8.
19. Yamada Y, Sugita S, Tanaka H, et al. Timing of recurrent uveitis in patients with Behçet's disease receiving infliximab treatment. Br J Ophthalmol 2010. doi:10.1136/bjo.2009.168856.
20. Sugita S, Yamada Y, Mochizuki M. Relationship between serum infliximab levels and acute uveitis attacks in patients with Behçet's disease. Br J Ophthalmol 2010. doi:10.1136/bjo.2009.174888.
21. Atmaca LS. Fundus changes associated with Behçet's disease. Graefe's Arch Clin Exp Ophthalmol 1989;227:340-4. (Pubitemid 19180482)
22. Cassoux N, Fardeau C, Lehoang P. Ocular manifestations of Behçet's disease. Ann Med Interne 1999;150:529-34.
23. Svenson M, Geborek P, Saxne T, et al. Monitoring patients treated with anti-TNF-α biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007;46:1828-34. (Pubitemid 350168300)